A trial of chemoradiotherapy, pembrolizumab, and olaparib for small cell lung cancer (KEYLYNK-013)

This trial is looking at adding a drug called pembrolizumab to chemoradiotherapy for newly diagnosed small cell lung cancer. It is also looking at having pembrolizumab on its own or with olaparib after chemoradiotherapy.

It is for people who:

• haven’t had treatment for small cell lung cancer and

• whose cancer is in only one lung. This is called limited small cell lung cancer.